The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2025

Filed:

Dec. 28, 2018
Applicant:

Cellectis, Paris, FR;

Inventors:

Alex Boyne, Jersey City, NJ (US);

Laurent Poirot, Paris, FR;

Philippe Duchateau, Draveil, FR;

Alexandre Juillerat, New York, NY (US);

Assignee:

Cellectis, Paris, FR;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/41 (2025.01); A61K 40/42 (2025.01); A61K 40/50 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); C12N 15/87 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/418 (2025.01); A61K 40/4202 (2025.01); A61K 40/421 (2025.01); A61K 40/4212 (2025.01); A61P 35/00 (2018.01); C07K 16/2815 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); C12N 15/87 (2013.01); A61K 40/50 (2025.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/60 (2013.01); C12N 2510/00 (2013.01); C12N 2750/14143 (2013.01);
Abstract

A method for engineering less alloreactive immune cells, including T-cells that express chimeric antigen receptors (CARs), using a nucleotide sequence in form of an RNA encoding a anti-TCR CAR to achieve the transient expression of anti-TCR CAR at the cell surface. The transient expression of the anti-TCR CAR recognized by the alpha beta TCR on the cell surface unexpectedly enabled the a purification of the TCR-negative CAR expressing cells. The TCR-negative CAR expressing immune cells can be used in adoptive therapy to treat diseases associated with cell surface antigens, such as cancer with less side effects, in particular less GVHD.


Find Patent Forward Citations

Loading…